A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Published:2010-03 Issue:3 Volume:21 Page:540-547
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Treat J.A.,Gonin R.,Socinski M.A.,Edelman M.J.,Catalano R.B.,Marinucci D.M.,Ansari R.,Gillenwater H.H.,Rowland K.M.,Comis R.L.,Obasaju C.K.,Belani C.P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/3/540/397481/mdp352.pdf

Reference61 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Screening, diagnosis, and staging of lung cancer;Shepherd;Curr Opin Oncol,1993

3. Chemotherapy for advanced non-small-cell lung cancer;Walling;Respir Med,1994

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials;Non-small Cell Lung Cancer Collaborative Group;BMJ,1995

5. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?;Grilli;J Clin Oncol,1993

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines;ESMO Open;2023-02

2. The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer;Cancer Treatment and Research Communications;2023

3. Non-Small Cell Lung Cancer in Older Adults with Frailty;Frailty in Older Adults with Cancer;2022

4. The best regimens for chemo-naïve incurable non-squamous non- small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis;Translational Lung Cancer Research;2021-08

5. A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis;Cancer Cell International;2020-11-10